Phantomix, Hospital-grade Heart MRI AI Diagnosis Initiated

[Financial News] Medical AI specialist company Phantomix is accelerating the distribution of automatic heart MRI diagnostic solutions targeting the hospital-grade market.
Phantomix announced on the 27th that it signed a strategic business agreement (MOU) with Hwaho Hospital, a general hospital in Suwon, on the 25th and will introduce the AI-based heart diagnostic solution 'Myomix'. This agreement is the first case to verify the actual applicability and operational efficiency in hospital-grade medical institutions and is expected to serve as a foothold for nationwide expansion in the future.
Myomix is a solution that automates heart MRI analysis used in diagnosing major diseases such as myocardial infarction and heart failure with AI. The examination, which used to take more than an hour, is shortened to within 30 minutes, and everything from image analysis to clinical report generation is processed automatically. AI comprehensively analyzes complex data such as delayed enhancement (LGE), 'T1/T2 mapping', and blood flow imaging to achieve biopsy-level precision.
Kim Pangi, CEO of Phantomix, emphasized, “AI-based automation improves both diagnostic time and accuracy,” and “the collaboration with Hwaho Hospital will be a turning point proving the clinical applicability of the technology.”
Hwaho Hospital, which opened in 2019, is the first general hospital in Gwonseon-gu, Suwon, equipped with high-level medical capabilities in 17 departments, including cardiovascular, cerebrovascular, and joint centers, with 35 specialists. Phantomix sees this hospital not as a mere customer but as a 'strategic partner for AI precision diagnostics'.
Under this agreement, Phantomix supports the overall digital transformation of the hospital field, going beyond simple software (SW) installation to designing imaging protocols, improving workflows, and establishing clinical operation models. CEO Kim said, “The AI transition of hospital-grade medical institutions is a core strategy for domestic medical innovation,” and “it will be an opportunity to bridge the gap between technology and clinical practice.”
Lee Seho, director of Hwaho Hospital, also stated, “This agreement is the beginning of establishing a future precision diagnostic system beyond mere technology introduction,” and “we will provide heart diagnostics at the level of upper-tier hospitals to local patients.”
Meanwhile, Phantomix is currently supplying solutions to major domestic upper-tier general hospitals such as Seoul Asan Hospital, Severance Hospital, and Seoul National University Hospital, as well as 19 hospitals in 5 countries overseas, including the United States, Japan, and Thailand. It has been recognized for its technological prowess through FDA certification and the CES Innovation Award. This agreement is the first case for nationwide expansion in hospital-grade medical institutions and is expected to be fully operational in the second half of this year.

jimnn@fnnews.com Shin Jimin Reporter